Pharming Wins First APDS Label for Children Aged Four Through Eleven
The FDA approved expanded Joenja dosing on 11 September 2026 for children aged four to eleven with APDS who weigh at least 27 kg, making leniolisib the first approved treatment for that pediatric cohort in the United States.
What changed
On 11 September 2026, Pharming Group announced U.S. Food and Drug Administration approval of a supplemental new drug application for Joenja (leniolisib) at 40 mg and 50 mg twice daily doses for children aged 4 to 11 years weighing at least 27 kg with activated phosphoinositide 3 kinase delta syndrome (APDS), a rare primary immunodeficiency.
Joenja was already approved for APDS patients aged 12 and older. Pharming expects the new pediatric doses to reach eligible U.S. patients through its specialty distribution network in October 2026.
Why it matters
APDS patients often present in childhood with recurrent infections, lymphadenopathy, and immune dysregulation. Expanding the label downward gives pediatric immunologists a targeted PI3K delta inhibitor rather than symptomatic management alone, which matters for formulary committees and rare disease centers planning multi year care pathways.
The approval rests on a Phase III open label single arm study in children 4 to 11 showing reduced lymphadenopathy and increased naive B cells over 12 weeks, with mild to moderate treatment emergent adverse events and no drug related serious adverse events reported.
Who is affected
Pediatric immunology practices, specialty pharmacy networks, and payers covering ultra rare disease drugs must prepare prior authorization templates for the new strengths. Competing PI3K pathway programs in primary immunodeficiencies should expect tighter comparative evidence requests from hospital pharmacy and therapeutics committees.
Investors in rare disease biotech will read the sNDA as proof Pharming can extend Joenja lifecycle without new molecular entities.
What to do next
If your center treats APDS families, confirm weight based dosing tables for the 40 mg and 50 mg strengths and update patient assistance workflows before October availability. Document baseline lymph node measures if you participate in post marketing surveillance.
What to watch
October 2026 U.S. launch execution, real world adherence in school age patients, and whether European regulators follow with a matching pediatric indication filing.
Sources
- Primary. Pharming Group, FDA approves Joenja as first treatment for children with APDS in the U.S. (11 September 2026). Approval details, dosing, October availability, and Phase III support.
- Secondary. Reuters, US FDA approves Scholar Rock's muscle weakness drug (11 September 2026). Same day FDA rare disease context (Scholar Rock SMA approval).